C4 Therapeutics, Inc.
CCCC · NASDAQ
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
C4 Therapeutics, Inc. (CCCC) is a biotechnology company focused on developing novel therapeutics based on protein degradation technology. Their platform enables the creation of small molecules that bind to target proteins and induce their selective degradation. This innovative therapeutic strategy has the potential to treat a wide range of diseases, including cancer and neurodegenerative disorders. C4 Therapeutics collaborates with major pharmaceutical companies to develop and commercialize new drug candidates. Their goal is to bring innovative treatment options to patients with various diseases. Shares of C4 Therapeutics, Inc. (CCCC) may be an attractive investment opportunity for investors interested in advanced therapeutic technologies and the biotechnology sector.
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew J. Hirsch
Employees
104
Headquarters
Watertown
Upcoming events
Earnings
Upcoming earnings report